Segment Information (Tables)

9 Months Ended

Sep. 30, 2021

Schedule of net product sales, cost of product sales and gross profit for each commercial products

Net product sales, cost of product sales, and gross profit for each of our commercial products were as follows (in millions):


	Three Months Ended September 30,
2021		Tyvaso(1)		Remodulin(1)		Orenitram		Unituxin		Adcirca		Total
Net product sales		$	164.2	$	125.4	$	85.2	$	55.3	$	14.6	$	444.7
Cost of product sales		7.8		6.9		4.5		2.4		6.1		27.7
Gross profit		$	156.4	$	118.5	$	80.7	$	52.9	$	8.5	$	417.0

2020
Net product sales		$	129.5	$	124.5	$	74.7	$	37.6	$	13.8	$	380.1
Cost of product sales		5.0		4.9		5.1		2.9		6.1		24.0
Gross profit		$	124.5	$	119.6	$	69.6	$	34.7	$	7.7	$	356.1

	Nine Months Ended September 30,
2021		Tyvaso(1)		Remodulin(1)		Orenitram		Unituxin		Adcirca		Total
Net product sales		$	441.0	$	395.4	$	233.8	$	152.3	$	47.8	$	1,270.3
Cost of product sales		20.6		23.5		12.4		11.0		20.4		87.9
Gross profit		$	420.4	$	371.9	$	221.4	$	141.3	$	27.4	$	1,182.4

2020
Net product sales		$	351.6	$	388.8	$	219.1	$	93.2	$	45.7	$	1,098.4
Cost of product sales		14.7		16.2		13.7		9.1		19.6		73.3
Gross profit		$	336.9	$	372.6	$	205.4	$	84.1	$	26.1	$	1,025.1

(1) Net product sales and cost of product sales include sales of delivery devices for the respective product, including, with respect to Remodulin, the Remunity Pump.

Schedule of net revenues from external customers by geographic area

Geographic revenues are determined based on the country in which our customers (distributors) are located. Total revenues from external customers by geographic area are as follows (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
United States	$	412.1	$	369.0	$	1,178.1	$	1,046.5
Rest of World	32.6		11.1		92.2		51.9
Total	$	444.7	$	380.1	$	1,270.3	$	1,098.4

Schedule of revenue from two specialty pharmaceutical distributors in the United States as a percentage of total revenue

We recorded revenue from three distributors in the United States that exceeded 10 percent of total revenues. Revenue from these three distributors as a percentage of total revenues is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Distributor 1	49	%	56	%	50	%	56	%
Distributor 2	30	%	28	%	28	%	27	%
Distributor 3	10	%	10	%	11	%	8	%